$CLRBZ News
Last published 1d ago
- 1d agoCLRBCLRBWCLRBZCellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswirePresented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in Waldenström macroglobulinemia (WM)
- 1w agoCLRBCLRBWCLRBZCellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and ExpositionGlobeNewswireUpdated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3 trial-in-progress design as site
- 1w agoCLRBCLRBWCLRBZCellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026GlobeNewswireFLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of
- 2w agoCLRBCLRBWCLRBZCellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131GlobeNewswireDurable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a
- 3w agoCLRBCLRBWCLRBZCellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström MacroglobulinemiaGlobeNewswireSubgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months Initiation and
- 3mo agoCLRBCLRBWCLRBZCellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireSite Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program Presented Data from CLOVER WaM Trial
- 3mo agoCLRBCLRBWCLRBZCellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026GlobeNewswireFLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of
- 3mo agoCLRBCLRBWCLRBZCellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal CancersGlobeNewswireDemonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted Radiotherapeutic Across